Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Stoke Therapeutics (NASDAQ: STOK) is a clinical-stage biotechnology company dedicated to addressing the underlying cause of severe genetic diseases by developing precisely targeted medicines that restore protein expression to near-normal levels. The company is pioneering a proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), to design and develop antisense oligonucleotides (ASOs) that selectively increase protein production from the healthy copy of a gene, thereby compensating for the non-functional or missing protein in genetic disorders. Stoke's initial focus is on diseases of the central nervous system and the eye, including Dravet syndrome and autosomal dominant optic atrophy (ADOA). Their lead candidate, STK-001, is in clinical development for Dravet syndrome. Stoke aims to transform the lives of patients and their families by delivering disease-modifying therapies.
The headquarters in Bedford serves as the central hub for Stoke Therapeutics' research and development, clinical operations, and corporate functions. It houses state-of-the-art laboratories and office spaces.
Modern laboratory facilities designed for advanced RNA-targeting research and oligonucleotide development. Collaborative workspaces fostering innovation among scientific and corporate teams.
Stoke Therapeutics fosters a science-driven, patient-focused, and collaborative work environment. Employees are motivated by the potential to make a significant impact on the lives of individuals with severe genetic diseases. Emphasis is placed on innovation, teamwork, and scientific rigor.
Located within the Greater Boston biotech cluster, one of the world's leading hubs for life sciences innovation, providing access to talent, research institutions, and industry collaborations.
While headquartered in the United States, Stoke Therapeutics' clinical development programs, such as for STK-001 in Dravet syndrome, involve trial sites in multiple countries including the U.S., Canada, U.K., and Australia. This gives the company an operational reach in terms of clinical research and patient engagement across several key regions. Their strategic collaborations and partnerships may also extend internationally, supporting their mission to bring novel therapies to patients worldwide.
45 Wiggins Avenue
Bedford
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Stoke Therapeutics' leadership includes:
Stoke Therapeutics has been backed by several prominent investors over the years, including:
In the past year, Stoke Therapeutics appointed Dr. Joan W. Miller as Chief Medical Officer. This followed the transition of Dr. Barry Ticho from the CMO role to a consultant position. Other key C-suite executive positions have remained stable during this period.
Discover the tools Stoke Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Stoke Therapeutics commonly utilizes an email format consisting of the employee's first initial followed by their last name. While other formats could potentially exist within the organization, this pattern is prevalent.
flast@stoketherapeutics.com
Format
ekaye@stoketherapeutics.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Stoke Therapeutics reported its Q1 2024 financial results, highlighting progress in its STK-001 program for Dravet syndrome and STK-002 for ADOA. The company discussed ongoing clinical trials, patient enrollment, and upcoming data readouts....more
GlobeNewswire • March 7, 2024
Stoke announced its 2023 year-end financials and provided updates on its clinical programs, including advancements in STK-001 for Dravet syndrome and STK-002 for ADOA, and outlined key anticipated milestones for 2024....more
GlobeNewswire • October 2, 2023
Stoke Therapeutics announced the appointment of Joan W. Miller, M.D., as its new Chief Medical Officer, effective October 2, 2023. Dr. Miller brings significant experience in ophthalmology and clinical development to the company....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Stoke Therapeutics, are just a search away.